Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Holdings (OTCQX: COSM) has launched a new dietary supplement, Osteodome, designed to enhance bone, cartilage health, and joint flexibility. The product is part of the Sky Premium Life line and targets normal bone function and muscle performance. Following the recent expansion of its EU distribution network to 1,500 pharmacies, the company anticipates Osteodome to significantly contribute to growth and profitability in 2021. The launch follows a previous product release, Bodyguard, aimed at bolstering immune health during the ongoing pandemic.
Cosmos Holdings has appointed Peter Goldstein to its Board of Directors and entered into an advisory agreement with PGS Ventures B.V. to assist in mergers and acquisitions and strategic planning. Goldstein brings over 30 years of experience in international business, including successful IPOs and mergers. His role will focus on evaluating potential acquisition targets to boost top-line revenues and EBITDA, with a goal of uplisting Cosmos Holdings to a senior exchange. The company aims to leverage his expertise to enhance shareholder value.